Delft Instruments has increased its interest in Rogan Medical Systems from 35% to 52%. Rogan, which markets its PACS software worldwide under the name HyperPACS, will continue to trade as a separate Delft operating company. Rogan already
Delft Instruments has increased its interest in Rogan Medical Systems from 35% to 52%. Rogan, which markets its PACS software worldwide under the name HyperPACS, will continue to trade as a separate Delft operating company. Rogan already collaborates with two other Delft companies: Nucletron for radiotherapy and thorax imaging and Oldelft Benelux for equipment distribution and maintenance.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.